Page last updated: 2024-11-12

gantacurium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gantacurium: Neuromuscular Depolarizing Agents; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10102486
CHEMBL ID1182997
SCHEMBL ID2606283
SCHEMBL ID3823451
MeSH IDM0420669

Synonyms (14)

Synonym
ZQLDXCSTJFLRPY-RWBXLJKRSA-N
CHEMBL1182997
gantacurium
758669-50-0
n9vk9zo25e ,
unii-n9vk9zo25e
gantacurium ion
gantacurium cation
SCHEMBL2606283
DTXSID90226772
SCHEMBL3823451
DB05710
Q27284755
4-o-[3-[(1s,2r)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propyl] 1-o-[3-[(1r,2s)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propyl] (z)-2-chlorobut-2-enedi

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" These data were then used to guide bolus dosing in multiples of ED95 in six dogs instrumented for hemodynamic measurements as well as inspiratory pressure and pulmonary compliance."( Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs.
Hashim, M; Heerdt, PM; Kang, R; Mook, RJ; Savarese, JJ; The', A, 2004
)
0.32
" Bolus dosing produced no cardiopulmonary change until a decrease in mean arterial pressure was elicited in four of six dogs at 25 x ED95."( Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs.
Hashim, M; Heerdt, PM; Kang, R; Mook, RJ; Savarese, JJ; The', A, 2004
)
0.32
" This occurs because of dosing choices for neuromuscular blocking agents and anticholinesterases as well as insensitivity of typically used monitors of depth of NMB."( Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents.
Lien, CA, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (61.11)29.6817
2010's6 (33.33)24.3611
2020's1 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.75 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index45.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (38.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (61.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]